Age-Related Meibomian Gland Dysfunction
年龄相关的睑板腺功能障碍
基本信息
- 批准号:8714514
- 负责人:
- 金额:$ 6.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-30 至 2015-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acinar CellAcinus organ componentAdipocytesAgingAgonistApoptosisAtrophicBindingCell Culture SystemCell LineCell NucleusCell ProliferationCellsCytoplasmDevelopmentDown-RegulationDuct (organ) structureEye diseasesEyelid DiseasesEyelid structureGene ExpressionGene Expression ProfileGenesGlandGoalsHumanImageKnowledgeLigandsLipidsMeasuresMicroscopyMolecularMusNuclearNuclear ReceptorsOperative Surgical ProceduresOpticsPPAR gammaPhosphorylationPopulationPost-Translational Protein ProcessingPrevalenceRaman Spectrum AnalysisRecruitment ActivityRegulationRoleSerineSimian virus 40TestingTissuesWestern Blottingabstractingage effectage relatedaging populationbaseeye drynesshuman NCOR1 proteinin vivolipid biosynthesismeibomian glandmeibomian gland dysfunctionnovelnovel therapeuticspromoterreceptorresponsetomographytool
项目摘要
Project Summary/Abstract
The long-term goal of this project is to understand the mechanism of age-related meibomian gland dysfunction
(MGD) and evaporative Dry Eye. Recently we have shown that mouse and human meibomian glands undergo
specific age-related changes including decreased acinar cell proliferation, acinar atrophy, and altered
peroxisome proliferator-activated receptor gamma (PPARg) localization from cytoplasmic-vesicluar/nuclear in
young to nuclear in old mice and humans. Since PPARg is a lipid sensitive, nuclear receptor implicated in
regulating adipocyte and sebocyte differentiation and lipogenesis, our findings suggest that PPARg may be
involved in modulating meibomian gland differentiation during aging. Based on these findings we propose that
aging of the meibomian gland may result in down-regulation of PPARg leading to decreased meibocyte
differentiation and lipid synthesis, gland atrophy, and a hyposecretory MGD. Currently, there is a
MAJOR GAP in knowledge regarding the role of PPARg in meibomian gland function. To test this
hypothesis we have develop novel imaging and cell culture systems to assess gland volume, lipid synthesis
and their regulation by PPARg. Using non-linear optical (NLO) microscopy and array tomography we have
volumetrically reconstructed the mouse meibomian gland and measured total, cellular and lipid volumes in
young and old glands. Preliminary studies suggest that atrophy of aging meibomian glands involves a marked
loss in the lipid volume suggesting decreased meibocyte differentiation. Additionally, we have used coherent
anti-stokes raman spectroscopy (CARS) to identify the regional lipid profiles within the meibomian gland and
have tentatively shown that there is an age-related change in the maturation of meibomian gland lipids moving
from the acini into the duct. Furthermore, we have developed an SV40 immortalized mouse meibocyte cell line
that synthesizes lipids and expresses PPARg. Using these novel tools we propose the following Specific Aims.
(1). Establish the age-related changes in PPARg localization and associated gene expression patterns by
quantifying the subcellular localization, post-translational modification and downstream response gene
expression patterns in the mouse and human meibomian gland. (2) Determine the effects of aging on the
meibomian gland by quantifying the volume and lipid synthesis using NLO microscopy and array tomography
to volumetrically reconstruct the meibomian gland and CARS to assess regional changes in lipid components
present in the acini, ductule and duct of the mouse and human meibomian gland. (3) Assess the effects of
natural and synthetic PPARg ligands on lipid synthesis by quantifying the subcellular localization, post-
translational modification and downstream response gene expression patterns in cultured mouse meibocytes.
(4) Measure the effect of PPARg ligands on meibocyte differentiation in vivo by quantifying the changes in
PPARg expression, meibocyte proliferation, gland volume and lipid synthesis in young and old mouse
meibomian glands.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James V Jester其他文献
James V Jester的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James V Jester', 18)}}的其他基金
Non-linear Optical Collagen Cross-linking (NLO CXL) for Treatment of Keratoconus
非线性光学胶原交联 (NLO CXL) 治疗圆锥角膜
- 批准号:
10391522 - 财政年份:2014
- 资助金额:
$ 6.35万 - 项目类别:
Non-linear Optical Collagen Cross-linking (NLO CXL) for Treatment of Keratoconus.
用于治疗圆锥角膜的非线性光学胶原交联 (NLO CXL)。
- 批准号:
8752184 - 财政年份:2014
- 资助金额:
$ 6.35万 - 项目类别:
Non-linear Optical Collagen Cross-linking (NLO CXL) for Treatment of Keratoconus
非线性光学胶原交联 (NLO CXL) 治疗圆锥角膜
- 批准号:
10222916 - 财政年份:2014
- 资助金额:
$ 6.35万 - 项目类别:
Non-linear Optical Collagen Cross-linking (NLO CXL) for Treatment of Keratoconus
非线性光学胶原交联 (NLO CXL) 治疗圆锥角膜
- 批准号:
10611375 - 财政年份:2014
- 资助金额:
$ 6.35万 - 项目类别:
Non-linear Optical Collagen Cross-linking (NLO CXL) for Treatment of Keratoconus.
用于治疗圆锥角膜的非线性光学胶原交联 (NLO CXL)。
- 批准号:
9303387 - 财政年份:2014
- 资助金额:
$ 6.35万 - 项目类别:














{{item.name}}会员




